Nationwide prevalence and drug treatment practices of inflammatory bowel diseases in Hungary: A population-based study based on the National Health Insurance Fund database

Kürti, Zsuzsanna; Végh, Zsuzsanna; Golovics, Petra A.; Fadgyas-Freyler, Petra; Gecse, Krisztina; Gönczi, Lóránt; Gimesi-Országh, Judit; Lovász, Barbara D.; Lakatos, László

doi:10.1016/j.dld.2016.07.012

Cited by 38 publications

(24 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on the present study findings, however, we believe that using at least two records of IBD diagnosis for case definition, as well as excluding the most recent 2 years of observation, will result in more accurate estimates of incidence. This requirement of at least two IBD records as case definition criteria is in line with two recent studies from large patient registries from Sweden and Hungary . Finally, when preparing studies based on NPR the fact that the number of incident patients decreases in the most recent observation years when requiring more than one record in the NPR should be taken into consideration.…”

Section: Discussionsupporting

confidence: 58%

The incidence of inflammatory bowel disease in Denmark 1980–2013: a nationwide cohort study

Lophaven

Lynge

Burisch

2017

Aliment Pharmacol Ther

128

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 58%

The incidence of inflammatory bowel disease in Denmark 1980–2013: a nationwide cohort study

Lophaven

Lynge

Burisch

2017

Aliment Pharmacol Ther

128

View full text Add to dashboard Cite

show abstract

“…ECCO Guidelines recommend the use of thiopurines for the maintenance of remission (1). Our results are in concordance with our neighbours' from Hungary (3). ULCERATIVE COLITIS In this group, 82.5% were treated with aminosalicylates, 37% with immunosuppressive drugs, 17% with corticosteroids and 11% with biologic therapy.…”

Section: Crohn's Diseasesupporting

confidence: 92%

Inflammatory Bowel Diseases: Focus on Therapy

Tecchio

Carmen

Alexandrescu

et al. 2018

ARS Medica Tomitana

View full text Add to dashboard Cite

INTRODUCTION: Medical management of Inflammatory Bowel Diseases is complex and tailored to disease activity. The primary goal is the induction of remission and maintenance of remission with longterm prevention of disease progression. AIM: to describe current drug treatment practices in Inflammatory Bowel Diseases in Dobrogea. MATERIAL AND METHOD: The retrospective and descriptive study included 128 patients: group 1 = Crohn’s Disease (79), group 2 = Ulcerative Colitis (46) and group 3 = Unclassified Colitis (3). RESULTS: The phenotypic distribution was: 62% with Crohn’s Disease, 36% with Ulcerative Colitis and 3 patients with Unclassified Colitis. CROHN’S DISEASE: According to Montreal Classification, the majority of patients were diagnosed after 40 years (58%); the most frequent involvement was ileo-colonic (47%) and the most frequent phenotype was inflammatory (60%). 40% patients had intestinal complications and 7% had extraintestinal complications. 16.4% required surgical interventions. 67% were treated at some point with aminosalicylates, 44% with immunosuppressive drugs (thiopurines), 80% with corticosteroids for the induction of remission (inaugural flare) and 50% of them received again corticosteroidssteroids in the evolution of the disease, and 29% with biologic therapy. ULCERATIVE COLITIS: Most common location was left colitis in 47% cases. One patient had intestinal complications and no extraintestinal complications were reported in this group. No patients required surgical interventions. 82.5% were treated at some point with aminosalicylates, 37% with immunosuppressive drugs (thiopurines), 17% with corticosteroids and 11% with biologic therapy. UNCLASSIFIED COLITIS: In this group were not reported intestinal and extraintestinal complications and also no patient required surgical interventions. 2 patients were treated at some point with aminosalicylates, all patients were treated with immunomodulators and only one patient was administered biologic therapy. CONCLUSIONS: Particularities of Crohn’s Disease in our region are: widespread use of aminosalicylates, overuse of corticosteroids overtime, underprescribed biologic therapy.

show abstract

“…This finding was somewhat surprising as it appears to contradict guideline recommendations, which recommend that biologics are used in steroid-dependent/refractory disease [1][2][3]. The rate of first-line biologic prescribing was also higher than has been reported in studies from other countries and regions [17][18][19][20][21][22][23], although this may be associated with the population selected for this study in which only patients who received biologics as part of their treatment course were included in the analysis. When these data were analyzed by whether intestinal inspection had been performed, patients who had undergone intestinal inspection in the 12 months prior to biologic introduction had a numerically lower rate of first-line biologic use (either as monotherapy or in combination with other drugs) and a statistically longer time from first CD diagnosis to biologic introduction (mean of 9.4 vs 0.9 months, respectively), compared with patients who had not undergone these investigational procedures.…”

Section: Discussioncontrasting

confidence: 56%

Imaging and treatment patterns in newly-diagnosed patients with Crohn’s disease: analysis of a Japanese claims database

Hirai

Uda

Ota

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: The biologics adalimumab, infliximab, and ustekinumab are approved to treat Crohn’s disease (CD) in Japan; they are recommended to induce/maintain remission in steroid-dependent/steroid-refractory CD. However, little is known about biologic use in real-world clinical practice, particularly in the initial treatment stage following endoscopic/radiographic diagnosis (intestinal inspection). Methods: This observational, retrospective, longitudinal cohort study assessed patients in the Japan Medical Data Center claims database who were diagnosed with CD from 2009–2019, and prescribed ≥ 1 biologic (adalimumab, infliximab, ustekinumab). Primary outcomes were type of first-line treatment prescribed on/within 6 months of first CD diagnosis, and time from first diagnosis to biologic introduction. Results: The study included 1346 patients with newly-diagnosed CD who were prescribed a biologic (adalimumab, n = 434; infliximab, n = 892; ustekinumab, n = 20). Most common first-line treatments were 5-aminosalicylic acid (5-ASA) monotherapy (26.8%), 5-ASA plus biologic (26.3%), and biologic monotherapy (12.9%). First-line steroids (monotherapy/in combination) were prescribed in 10.8% of patients. The first-line biologic prescription rate was lower in patients who had undergone intestinal inspection within 12 months before biologic introduction versus those who had not (5.3% vs 17.4% in monotherapy; 19.9% vs 65.4% in combination with other agents). Mean time from diagnosis to first biologic prescription was 4.1 months. Conclusions: The study demonstrated high use of biologics (particularly infliximab) and low use of steroids in initial treatment of Japanese patients with newly-diagnosed CD who received biologics during their treatment course. Biologic prescription was more common in patients who had not undergone prior intestinal inspection.

show abstract

Nationwide prevalence and drug treatment practices of inflammatory bowel diseases in Hungary: A population-based study based on the National Health Insurance Fund database

Cited by 38 publications

References 34 publications

The incidence of inflammatory bowel disease in Denmark 1980–2013: a nationwide cohort study

The incidence of inflammatory bowel disease in Denmark 1980–2013: a nationwide cohort study

Inflammatory Bowel Diseases: Focus on Therapy

Imaging and treatment patterns in newly-diagnosed patients with Crohn’s disease: analysis of a Japanese claims database

Contact Info

Product

Resources

About